AUPH News and Press, Aurinia Pharmaceuticals Inc From 06/20/23

LUPKYNIS® achieved significantly earlier reductions in UPCR and significantly higher renal response rates in lupus nephritis patients with high proteinuria, compared to patients treated with mycophenolate mofetil and low-dose steroids alone, in a pooled, post-hoc analysis. 1 LUPKYNIS...

2023-06-16 15:57:44 ET Summary In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34.4 million. Full-year 2023 revenue guidance range was increased to between $135 to $155 million of ...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the results of a post-hoc, pooled analysis of the Phase 2 AURA-LV (NCT02141672) and Phase 3 AURORA 1 (NCT03021499) studies, which found that LUPKYNIS® with mycophenolate mofetil (MMF) and low-dose steroids r...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced the filing of a registration statement on Form S-8 with the United States Securities and Exchange Commission (SEC). Under U.S. federal securities laws, equity awards issued as employee compensation must be re...

2023-05-22 04:15:56 ET Summary Two of Aurinia's largest shareholders wrote tough letters against the AUPH board, leading to two resignations. One of these shareholders also wanted AUPH to sell out. While a sale has been put on hold for now, any further poor performance will st...

2023-05-17 17:21:57 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 5% in regular trading as two board members, including the chairman, resigned from the board after receiving less than majority support in a shareholder vote on Wednesday. Chairman George Milne and board m...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced voting results for its annual general meeting (the “Meeting”) of shareholders held on May 17, 2023. Shareholders re-elected six of eight incumbent directors to th...

2023-05-11 14:02:17 ET The largest shareholder of Aurinia Pharmaceuticals ( NASDAQ: AUPH ) said it plans to withholder support for seven board members at the company's upcoming annual meeting. Iljin SNT, which has a 6.1% stake, said it plans to withhold support from seven board ...

First study to assess histologic changes in the kidneys of patients with lupus nephritis treated with LUPKYNIS ® (voclosporin) Treatment was not associated with chronic injury, with the average chronicity index remaining stable in both treatment arms from baseline to follow-up ...

2023-05-04 13:08:04 ET Start Time: 08:30 End Time: 09:27 Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR ...